Introduction
============

Chronic obstructive pulmonary disease (COPD) is believed to be the third leading cause of death worldwide by 2020 ([@B78]).

Chronic obstructive pulmonary diseases is a common disease characterized by respiratory symptoms and progressive airflow obstruction due to alveolar and bronchial abnormalities and inflammation caused by exposition to noxious substances ([@B25]). COPD is associated to dyspnea, cough, and sputum with lung hyperinflation. COPD is a disabling disease with huge impact on normal daily activities and limiting quality of life, the disease abruptly worsen due to exacerbations inducing a step down of health conditions, following which the recovery of breath function and activities is gradually slower and more difficult leading to disability and death ([@B25]).

Following this series of reasons there is a great impulse in the development of drugs able to improve symptoms, quality of life, reduce exacerbations, hospitalizations and the frequency of death of patients with COPD. The cornerstones of treatment are bronchodilator drugs of different classes including beta agonists and muscarinic antagonists ([@B48]).

Currently the Global initiative for COPD (GOLD) promotes the "ABCD" assessment of COPD patients based on symptoms severity (assessed by questionnaire) and exacerbation risk (low risk consisting in no more than one moderate -- severe exacerbation during the past year). GOLD group A includes patients with low symptom severity and low exacerbation risk. GOLD group B includes patients with high symptom severity and low exacerbation risk. GOLD group C includes patients with low symptom severity but high exacerbation risk. GOLD group D includes patients presenting high symptom severity and high exacerbation risk ([@B25]).

Global initiative for COPD suggests the use of long acting beta agonists (LABA) and long acting muscarinic antagonists (LAMA) in combination for group B patients with persistent symptoms, group C patients with further exacerbations on LAMA treatment and for group D patients with or without the addition of inhaled corticosteroids (ICSs).

The administration of these two drugs simultaneously with the same device (single inhalator) should ensure a better adherence to the treatment and ad hoc dosages to produce a "synergistic effect between the two drugs respect to the administration of the two drugs separately ([@B67]).

Currently the LAMA/LABA combination in single inhaler device disposable on the market include Umeclidinium/ Vilanterol (Anoro^®^), Tiotropium/Olodaterol (Stiolto^®^), Glycopyrrolate/Formoterol (Bevespi^®^) and Glycopyrronium/Indacaterol (Ultibron^®^) available in the United States. Glycopyrronium/Indacaterol (Ultibro^®^), Tiotropium bromide/Olodaterol (Spiolto^®^), Umeclidinium/Vilanterol (Anoro^®^), and Aclidinium/Formoterol (Duaklir^®^ Genuair^®^, Brimica^®^ Genuair^®^) are available in the European Union ([Table 1](#T1){ref-type="table"}).

###### 

LAMA/LABA fixed dose combinations licensed in different countries.

  Drugs FDC         Dosage (μg)   Brand name    Device                 Country
  ----------------- ------------- ------------- ---------------------- -----------
  Umeclidinium      55            Anoro^®^      Ellipta (DPI)^®^       US and EU
                                                                       
                                                                       
  Vilanterol        22                                                 
  Tiotropium        5             Spiolto^®^    Respimat (SMI)^®^      EU
                                                                       
                                                                       
  Olodaterol        5             Stiolto^®^                           US
  Glycopyrronium    50            Ultibro^®^    Breezhaler (DPI)^®^    EU
                                                                       
                                                                       
  Indacaterol       110                                                
  Glycopyrronium    15,6          Ultibron^®^   Neohaler (DPI)^®^      US
                                                                       
                                                                       
  Indacaterol       27,5                                               
  Glycopyrronium    9             Brevespi^®^   Aerosphere (pMDI)^®^   US
                                                                       
                                                                       
  Formoterol Fum.   4.8                                                
  Aclidinium        340           Brimica^®^    Genuair (DPI)^®^       EU
                                                                       
                                                                       
  Formoterol Fum.   12            Duaklir^®^                           
  Tiotripium        9 or 18       Duova^®^      DPI                    Lebanon
                                                                       
                                                                       
  Formoterol Fum.   6 or 12       Tioform^®^                           India
                                                                       

LAMA, long acting muscarinic antagonist; LABA, long acting beta agonist; FDC, fixed doses combination; DPI, dry powder inhaler; US, United States; EU, European Union; SMI, soft mist inhaler; pMDI, pressurized metered dose inhaler; Fum., fumarate.

Purpose of this review is providing a complete criticism of LAMA/LABA single inhaler treatment in COPD with particular mention to the most debated topics and future prospects in the field.

Pharmacology Mechanism of Action and Rationale for LAMA/LABA Fixed Dose Combinations in a Single Inhaler for COPD
=================================================================================================================

Long acting beta agonist and LAMA are two major classes of bronchodilators and currently the principal medications for patients with COPD. LABA relax airway smooth muscle by linking with the beta2-adrenergic receptors. This linkage cause bronchodilation by inducing conformational changes in the post-synaptic β2 receptor on airway smooth muscle cells with consequent activation of a stimulatory guanosine-threephosphate-(GTP) binding protein (G2), increased adenylyl cyclase activity and cyclic adenosine monophosphate (cAMP) synthesis, Protein Kinase A activation and sequential intracellular events, including inhibition of myosin light chain kinase (MLCK), leading to reduction in smooth muscle airway contractility. This relaxation is also caused by activation of large conductance Ca^2+^ activated K^+^ channels via G2 which leads to plasma membrane hyperpolarization ([@B49]) ([Figure 1](#F1){ref-type="fig"}).

![Parasympathic pathway involved in control of airway smooth muscle contraction. ACh, acetylcholine; M1, M1-muscarinic receptor; M2, M2-muscarinic receptor; M3, M3-muscarinic receptor.](fphar-10-00390-g001){#F1}

Long acting beta agonist can be divided into once-daily and twice-daily LABA. Once-daily LABA are currently called ultra-LABA. Ultra-LABA are ultra-long acting and are dosed once a day such as indacaterol (IND), olodaterol (OLO), and vilanterol (VIL); they provides both the quick bronchodilation effect similar to short-acting beta agonists, and a 24-h bronchodilation effect permitting the once-daily administration ([@B27]). Twice-daily LABAs are formoterol fumarate (FF) or propionate (FP) and salmeterol (SAL). LAMA block the bronchoconstrinction effect of acetylcholine on M3 muscarinic receptors expressed in airway smooth muscle; they have prolonged binding to M3 muscarinic receptors with faster dissociation from M2 muscarinic receptors ([@B25]). M3 receptors are coupled (GTP) -- binding protein (G2) which regulates intracellular calcium concentration and calcium-modulated proteins ([@B56]) ([Figure 2](#F2){ref-type="fig"}).

![Signaling pathway of β2 receptor activation. Gs, Gs-protein; AC, adenylate cyclase; ATP, adenosine triphosphate; cAMP, cyclic AMP; PKA, protein kinase A; MLCP, myosin light chain phosphatase.](fphar-10-00390-g002){#F2}

Long acting muscarinic antagonists such as tiotropium (TIO), umeclidinium (UMEC), and glycopyrronium (GLY) are long acting drugs and are dosed once a day, while aclidinium (ACL) is dosed twice a day.

Bronchodilator monotherapy is not always satisfactory for patients with advanced COPD. In that situation, a dual-bronchodilator therapy consisting of LAMA and LABA is a good option. LAMA/LABA fixed dose combinations (FDCs) have been shown to improve lung function, lung hyperinflation, exercise capacity, quality of life and exacerbation frequency thereby slowing disease progression in COPD ([@B25]). This combinations have a synergistic effect rather than just being additive one ([@B67]). Synergy is defined as the drug combination having a greater effect than would be expected from the mono-components alone. Synergy would be beneficial as a greater degree of bronchodilation could potentially be achieved at lower doses of the individual components thus minimizing side effects. LABAs activate pre-junctional β2-adrenoceptors and reduce acetylcholine release thereby prevent any functional competition by acetylcholine at post-junctional muscarinic receptors in the airways occupied by LAMAs. Thus LAMA/LABA combinations exploit both the adrenergic and cholinergic pathways in the airway smooth muscle to maximize bronchodilation ([@B34]) ([Figure 3](#F3){ref-type="fig"}).

![Interplay of adrenergic and cholinergic pathway on airway smooth muscle. ACh, acetylcholine; M2, M2-muscarinic receptor; M3,M3-muscarinic receptor.](fphar-10-00390-g003){#F3}

LAMA/LABA Fixed Dose Combinations in a Single Inhaler for COPD: Evidences From Clinical Trials
==============================================================================================

LAMA/LABA combinations in a single inhaler with fixed dose are numerous. Here we resemble the principle international studies on efficacy and safety of LAMA/LABA combinations.

The main published studies on LAMA/LABA single inhaler treatments are summarized in [Table 2](#T2){ref-type="table"}.

###### 

Main published studies on LABA/LAMA single inhaler for COPD.

  Drugs (reference)                  Competitor                  Duration (weeks)   ITT population   Main results                                                                                            
  ---------------------------------- --------------------------- ------------------ ---------------- ------------------------------------------------------------------------------------------------------- --
  UMEC/VIL 62.5/25 μg OD ([@B42])    TIO 18 μg OD                24                 1191             Improv. t-FEV~1~ and HRQL vs. TIO                                                                       
  UMEC/VIL 62.5/25 μg OD ([@B22])    SAL/FP 250/50 μg TD         12                 697              Improv. 0--24 h wmFEV~1~ and t-FEV~1~ vs. SAL/FP                                                        
  TIO/OLO 5/5 μg OD ([@B21])         TIO (various dosages)       52                 11 *trials*      Improv. Pulm Funct. and HRQL vs. PLAC                                                                   
                                     OLO (various dosages)                                                                                                                                                   
                                     PLAC                                                                                                                                                                    
  ENERGITO study                     SAL/FP 250/50 μg TD         6                  229              Improv. FEV~1~ AUC 0--12 and 0--24 vs. both competitors                                                 
  TIO/OLO 5/5 μg OD                  SAL/FP 500/50 μg TD                                                                                                                                                     
  TIO/OLO 5/2.5 μg OD ([@B8])                                                                                                                                                                                
  SHINE study                        IND 110 μg, GLY             26                 2144             Improv. t- FEV~1~ vs. monocomponents, TIO and PLAC                                                      
  QVA149 OD ([@B7])                  150 μg                                                                                                                                                                  
                                     TIO 18 μg, PLAC                                                                                                                                                         
                                     All OD                                                                                                                                                                  
  SPARK study                        GLY 50 μg OD                64                 2224             Reduced mod to severe exacerbations rate vs. both                                                       
  QVA149 OD ([@B77])                 TIO 18 μg OD                                                    Impov. t- FEV~1~ vs. both                                                                               
  FLAME study                        SAL/FP 50/500 μg TD         52                 3362             Reduced all severity exacerbation rate vs. competitor (reduced incidence of pneumonia vs. competitor)   
  QVA149 OD ([@B76])                                                                                                                                                                                         
  ILLUMINATE study                   SAL/FP 50/500 μg TD         26                 523              Improv. FEV~1~ AUC 0--12 vs. competitor                                                                 
  QVA149 OD ([@B75])                                                                                                                                                                                         
  LANTERN study                      SAL/FP 50/500 μg TD         26                 744              Improv. t-FEV~1~ vs. competitor (reduced incidence of pneumonia vs. competitor)                         
  QVA149 OD ([@B79])                                                                                                                                                                                         
  FLIGHT 1 and 2 and 3 study         GLY 15.6 μg TD              12                 2038             Improv. FEV~1~ AUC 0--12 vs. monocomponents and PLAC                                                    
  GLY/IND 15.6/27.5 μg TD ([@B41])   IND 27.5 μg TD                                                                                                                                                          
                                     PLAC                                                                                                                                                                    
  PINNACLE 1 and 2 study             GLY 18 μg TD                24                 3274             Improv. t-FEV~1~ vs. competitors                                                                        
  GLY/FF 18/9.6 μg TD ([@B46])       FF 9.6 μg TD                                                                                                                                                            
                                     TIO 18 μg OD (PINNACLE 1)                                                                                                                                               
                                     PLAC                                                                                                                                                                    
  PINNACLE 3                         GLY 18 μg TD                26                 892              Improv. tFEV~1~, RMU, TDI vs. monocomponents and TIO                                                    
  GLY/FF 18/9.6 μg TD ([@B26])       FF 9.6 μg TD                                                                                                                                                            
                                     TIO 18 μg OD                                                                                                                                                            
  ACLIFORM study                     ACL 400 μg TD               24                 1729             Both Improv. 1-h post-dose FEV~1~ vs. ACL 400 μg                                                        
  ACL/FF 400/12 μg TD                FF 12 μg TD                                                     Both Improv. t-FEV~1~ vs. FF 12 μg                                                                      
  ACL/FF 400/6 μg TD ([@B61])        PLAC                                                            Both Improv. TDI vs. PLAC                                                                               
  AUGMENT study                      ACL 400 μg TD               24                 1692             Both Improv. 1-h post-dose FEV~1~ vs. ACL 400 μg                                                        
  ACL/FF 400/12 μg TD                FF 12 μg TD                                                     ACL/FF 400/12 Improv. t-FEV~1~ vs. FF 12 μg                                                             
  ACL/FF 400/6 μg TD ([@B23])        PLAC                                                            ACL/FF 400/12 Improv. TDI and HRQL vs. PLAC                                                             
  TIO/FF 18/12 μg ([@B60])           TIO 18 μg                   Single dose        44               Faster bronchodilator response (FEV~1~, FVC) vs. TIO                                                    
                                                                                                     Improv. mean maximum change in FEV1, FVC vs. TIO                                                        
                                                                                                     Improv. FEV~1~, FVC and IC AUC (0--24 h) vs. TIO                                                        
                                                                                                                                                                                                             

UMEC, umeclidinium; VIL, vilanterol; OD, once daily; TIO, tiotropium; t-FEV

1

,

through forced expiratory volume at the first second; HRQL, health-related QVAlity of life; Vs, versus; SAL, salbutamol; FP, fluticasone propionate; TD, twice daily; wm, weighted mean; OLO, olodaterol; PLAC, placebo; AUC, area under curve; QVA149, glycopyrronium 50 μg + indacaterol 110 μg; GLY, glycopyrronium; IND, indacaterol; FF, fluticasone fumarate; TDI, transitional dyspnea index; RMU, rescue medication use; ACL, aclidinium; FVC, forced vital capacity; IC, inspiratory capacity.

Umeclidinium/Vilanterol
-----------------------

Numerous international clinical trials have evaluated the efficacy and safety of UMEC/VIL against placebo, monocomponents, TIO and associations between LABA and ICS ([@B43]). We summarize the principal studies: a 24 weeks trial UMEC/VIL 125/25 μg once daily (OD) was tested vs. UMEC 125 μg, VIL 25 μg and placebo (OD) in more than 1000 COPD patients. Combined treatment was superior to placebo and monocomponents in improving difference from baseline of through forced expiratory volume at the first second (tFEV~1~), transitional dyspnea index (TDI) and rescue medication use (RMu) ([@B15]).

Decramer and colleagues conducted two 24 weeks trial in more than 800 COPD patients (each study) testing UMEC/VIL 125/25 μg, UMEC/VIL 62.5/25 μg, TIO 18 μg, VIL 25 μg or UMEC 125 μg (all OD). They reported that both associations treatments were superior to TIO, UMEC, and VIL alone in improving tFEV~1~ and RMu ([@B19]). Another ([@B42]) 24-week, multicenter, randomized, blinded, double-dummy, parallel-group study Phase III study compared UMEC/VIL 62.5/25 μg, to TIO 18 μg OD. Significant improvements in trough FEV~1~ was observed for UMEC/VIL versus TIO. Also, UMEC/VIL improved health-related quality of life (HRQL), and reduced the requirement for RMu compared with TIO.

Three 12-week trials enrolling more than 2000 patients with COPD compared UMEC/VIL 62.5/25 μg OD with Salmenterol/Fluticasone propionate (SAL/FP) 250/50 μg twice daily (TD) and 500/50 μg TD ([@B22]; [@B63]). In these studies UMEC/VIL provided an improved of pulmonary function (mean change from baseline in tFEV~1~) in all trials. Only one study reported a reduction in RMu in favor of patients treated with UMEC/VIL ([@B22]).

In summary the considered trials concluded that once-daily UMEC/VIL 62.5/25 μg OD, was well-tolerated, provided clinically-significant improvements in lung function and symptoms in COPD patients.

UMEC/VIL 55--22 μg is commercialized with the name of Anoro^®^ and delivered by the Ellipta^®^ dry powder inhaler (DPI).

Tiotropium/Olodaterol
---------------------

The efficacy and safety of this combination was studied several randomized, double-blind, parallel-group, multicenter trials ([@B21]). In these studies, over 10,000 patients have been involved, for simplicity we consider only the dosage of 5/5 μg OD that is recommended and available on market. The majority of these studies involved patients with COPD GOLD II and III stage.

TIO/OLO 5/5 μg not only improved pulmonary function more than placebo but also resulted in statistically significant improvements on dyspnea, RMu, HRQL, and exercise endurance.

TIO/OLO 5/5 μg differed significantly from TIO 5 μg monotherapy in terms of pulmonary function \[FEV~1~ area under curve (AUC)0--24, FEV~1~ AUC0--12, and FEV~1~ AUC12--24\] and reducing symptoms of dyspnea (TDI and HRQ). Comparison between TIO/OLO 5/5 μg FDC OD and OLO 5 μg OD, was generally statistically but not clinically significant in favor of fixed dose association not reaching the minimal clinical important difference (MCID). In a 6-week trial that enrolled more than 200 patients with COPD, TIO/OLO 5/5 μg was significantly more effective than SAL/FP TD at improving pulmonary function (ENERGITO study) ([@B8]).

TIO/OLO 5/5 mg is formulated in the Respimat^®^soft-mist inhaler (SMI) commercialized under the name of Spiolto^®^(EU) or Stiolto^®^(US).

Glycopyronium/Indacaterol
-------------------------

The fixed-dose combination of LAMA GLY 50 μg plus LABA IND 110 μg (QVA149) has been shown in a series of clinical trials to be more effective than placebo and the single components with regard to lung function, symptoms, and quality of life outcomes, being as safe as the single components and placebo. All the considered studies were randomized double-blind.

SHINE study ([@B7]) is a multicenter, 26-week trial which evaluated the safety and efficacy in terms of tFEV 1 of QVA149 in comparison to IND, GLY, TIO, and placebo (OD) in patients with moderate-to-severe COPD. Trough FEV~1~ at week 26 was significantly improved with QVA149 compared to all other treatment arms, with a safety and tolerability profile similar to placebo.

SPARK ([@B77]) is a 64-week, parallel-group, active controlled study to evaluated the effect of QVA149 vs. GLY 50 μg and TIO 18 μg (OD) in 2224 patients with severe-to-very severe COPD (GOLD COPD stages III and IV and one or more moderate COPD exacerbation in the past year). QVA149 was found to significantly reduce the rate of moderate to severe COPD exacerbations by 12% compared to GLY, and by 10% compared to TIO; however, with not significant differences. QVA149 also significantly improved tFEV 1 and quality of life as compared to GLY and TIO without any increase in adverse events.

FLAME A 52-week multi-center, parallel-group, active controlled study to compare the effect of QVA149 OD with SAL/FP TD on the rate of exacerbations in 3332 patients with moderate-to-very severe COPD. QVA149 reduced the annual rate of all COPD exacerbations (the rate was 11% lower in the QVA149 group than in the SAL/FP group) ([@B76]).

ILLUMINATE study ([@B75]) is a 26 weeks parallel-group study, in which 523 patients with moderate to severe COPD were assigned to OD QVA149 or TD SAL/FP 500/50 μg. At week 26 FEV~1~ AUC 0--12 h was significantly higher with QVA149 than with SAL/FP, with a similar incidence of serious adverse events.

LANTERN is a 26-week parallel-group study conducted to assess the efficacy and safety of OD QVA149 compared to TD SAL/FP 500/50 μg in 744 patients with moderate-to-severe stable COPD with or without exacerbations in the previous year. QVA149 had significant superiority to SAL/FP for tFEV~1~ and for the standardized AUC from 0 to 4 h. QVA149 showed similar improvements in TDI focal score, St George Respiratory Questionnaire total score, and RMu compared to the other active arm. However, QVA149 significantly reduced the rate of moderate or severe exacerbations by 31% (*p* = 0.048) over SAL/FP. The incidence of pneumonia was threefold lower with QVA149 (0.8%) ([@B79]).

The FDA approved dose for GLY/IND in the US is 15.6/27.5 μg TD based on the FLIGHT1 and FLIGHT2 studies ([@B41]) while in the European Union the approved dose for GLY/IND is 50/110 μg OD. Studies have shown that the two formulations have similar effects. The EXPEDITION program consisted of FLIGHT 1, 2, and 3 studies which tested GLY/IND 15.6/27.5 μg TD in US. It has shown a significant improvement in lung function for the FDC compared to monocomponents and in HRQL and RMu compared to placebo ([@B41]).

GLY/IND association 50--110 μg is marketed in EU with the brand name of Ultibro^®^, delivered by Neohaler^®^DPI.

GLY/IND association 15,6--27,5 μg is marketed in United States with the brand name of Ultibron^®^, delivered by the Breezhaler^®^DPI.

Glycopyrrolate/Formoterol
-------------------------

Two 24-weeks, randomized, double blind, and placebo controlled phase III trials: PINNACLE-1 and PINNACLE-2 assessed the clinical efficacy and safety of GLY/FF 18/9.6 μg fixed dose association in patients with moderate and very severe COPD ([@B46]). Patients received GLY/FF, GLY 18 μg, FF 9.6 μg, or placebo (all TD), or TIO 18 μg. At the end of the trials patients were randomized to prosecute the trial for 52 w: PINNACLE-3 ([@B26]). At week 24, significant differences in change from baseline in the trough FEV~1~ for GLY/FF vs. placebo, GP, and FF were seen in both PINNACLE-1 and PINNACLE-2. The incidence of adverse events was similar between all treatment arms. Improvements in efficacy endpoints were also sustained over 52 weeks.

GLY/FF is delivered by a Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology and commercialized with the name of Bevespi^®^ (available only in US market).

Aclidinium/Formoterol
---------------------

Two 6-month, multicentre, randomized studies (ACLIFORM and AUGMENT) have evaluated the safety and efficacy of ACL/FF FDC. The first study ([@B61]) compared the 400/6 μg and 400/12 μg combinations of ACL/FF with ACL 400 μg, FF 12 μg and placebo (all TD). Both combinations demonstrated statistically significant improvements to placebo in from baseline in 1-h post-dose FEV~1~, tFEV~1~ in the changes in TDI. At week 24, both combinations showed significant improvements from baseline in 1-h post-dose FEV~1~ versus ACL and tFEV~1~ versus FF.

AUGMENT study ([@B23]) was conducted in 1692 stable COPD patients comparing ACL/FF 400/12 μg, ACL/FF 400/6 μg, ACL 400 μg, FF 12 μg, or placebo (all TD).

Statistically significant improvements at week 24 were observed in the co-primary endpoints of FEV~1~ 1-h post-dose, by the 400/12 μg combination of ACL/FF, versus 400 μg ACL and for tFEV~1~ versus FF 12 μg. The 400/6 μg combination produced statistically significant improvements in (FEV~1~) 1-h post-dose versus ACL, but for the change from baseline tFEV~1~ did not reach significance as compared to FF 12 μg. The 400/12 μg combination induced a Peak FEV~1~ improvement at 24 weeks by 285 ml versus placebo (*p* \< 0.0001) and the 400/6 μg combination by 259 ml with versus placebo (*p* \< 0.0001).

A pooled analysis of these two trials ([@B6]) revealed that 400/12 combination improved TDI focal score, HQRL, overall night-time and early-morning symptom severity versus placebo and both monotherapies at Week 24 (all *p* \< 0.05).

The rate of moderate or severe exacerbations was significantly reduced with ACL/FF 400/12 μg compared with placebo (*p* \< 0.05) but not monotherapies. 400/12 μg ACL/FF combination was the most effective dose and was found well-tolerated and safe.

ACL/FF 400/12 is commercialized with the names of Duaklir^®^ and Brimica^®^, delivered by the Genuair^®^ dry powder inhaler (available only in European market).

Tiotropium/Formoterol
---------------------

A single study enrolled 44 COPD subjects in a randomized, double-blind, multi-center, cross-over study. On two separate days 18 μg TIO and 18 μg TIO plus 12 μg FF (single dose) were administered via pressurized metered dose inhalers. The results showed that the combination of TIO plus FF showed a faster onset of bronchodilator response (*p* \< 0.01 for FEV~1~ and forced vital capacity FVC), a greater mean maximum change in FEV~1~ (*p* = 0.01) and FVC (*p* = 0.008) and greater AUC0--24 h values for FEV~1~, FVC and inspiratory capacity (IC) compared with TIO alone. In the combination treated group Trough FEV~1~ and FVC values were also improved ([@B60]).

TIO/FF is commercialized only in few countries with the name of DUOVA^®^ (Lebanon) with different dosages (9/6 mcg; 9/12 mcg and 18/12 mcg) and TIOFORM^®^ (India) 18/12 mcg; 9/6 mcg.

The Role of LAMA/LABA Fixed Dose Combinations in a Single Inhaler for COPD Therapy in Global Initiative for Obstructive Lung Disease Recommendations
====================================================================================================================================================

The rationale for fixed combination bronchodilator therapy in COPD is based on the increased bronchodilation and reduced side-effects compared to the single bronchodilators effects ([@B14]). Since 2011, and after their last revision, GOLD recommendations introduced ABCD assessment tool to classify patients in four groups depending on symptoms and their history of exacerbations. Together with clinical and functional evaluation, ABCD assessment is crucial for stratification of prognosis and to decide which is the better therapy for patients ([@B71]; [@B64]). In the management of stable COPD patients, the identification and reduction of exposure to risk factors are fundamental. The aim of pharmacological treatment is to reduce symptoms, the risk and severity of exacerbations in addition to improve health status and tolerance to exercise ([@B25]). Therapeutic decisions are strictly dependent to availability of medications and patient's response or preference; nevertheless, since drugs are delivered with inhalators, a proper inhaler technique is required to take correctly medicaments.

Global initiative for COPD recommendations provide a model for initiation of the treatment and for subsequent adjustments such as escalation and/or de-escalation according to following evaluation of symptoms control and risk of exacerbations. The combined therapy with LABA and LAMA plays an important role in therapeutic strategies three out of four ABCD groups:

**Group B:** in group B, characterized by patients with high symptoms burden but low number of moderate/severe exacerbations, the initial therapy should be based on a long acting bronchodilator, LABA or LAMA ([@B5]; [@B4]). In this group of patients, when there is the persistence of dyspnoea despite a monotherapy with a bronchodilator, it's recommended to add a second bronchodilator ([@B31]). This approach originates from the results of a meta-analysis that included four studies ([@B1]; [@B74]; [@B68]; [@B40]).

[@B1] investigated SAL and TIO, Vogelmeier FF and TIO; both studies demonstrated a significant reduction of St George's Respiratory Questionnaire (SGRQ) score, therefore an improvement of quality of life, for the group of patients in treatment with combined therapy LABA and TIO. Same studies did not report a reduction of hospital admission for any cause, neither for exacerbations. Taking into account the lung function, all the studies included in the meta-analysis demonstrated an improvement in pre-bronchodilator FEV~1~ at the end of the study for the LABA + TIO groups.

Recently [@B12] published a review and meta-analysis on duration of treatment of LABA and LAMA combinations in COPD patients; they included 14 studies that reported results of 20 randomized controlled trials. In these studies the drugs used for LAMA/LABA therapy were: GLY/IND, UMEC/VIL, TIO/OLO, ACL/FF with different regimens of administration (once or twice daily). LAMA/LABA significantly improved trough FEV~1~, SGRQ and TDI after 3, 6, and 12 months of treatment, when compared with monocomponents. Again [@B59] in a recent meta analysis demonstrated the effectiveness of dual broncodilation respect monocomponents, in particular for changes of through FEV~1~ when compared to LABA. The stability of the effect of combined therapy on FEV~1~ lasts for 12 months and remain stable and superior for the whole period of observation.

For those patients in group B that complain severe breathless, GOLD recommendations suggest to start with combination therapy. This approach originates from a study conduced by [@B45] that evaluated *post hoc* analysis of pooled data from PINNACLE-1 and PINNACLE-2 phase III studies, evaluating GLY/FF combination versus single components, on lung function, exacerbation and baseline symptom burden (measured with COPD Assessment Test, CAT) ([@B45]). The significant improvement of SGRQ score obtained by combination therapy respect to monotherapies was greater in those patients with baseline CAT score ≥ 20 points. Similar results have been obtained considering other clinical parameters such as function of baseline symptom burden.

The GOLD Guidelines authors recommended that if the addition of the second bronchodilator did not reduce symptoms, the treatment could be stepped down to a single bronchodilator (LABA or LAMA). In this case it's mandatory to evaluate or re-evaluate comorbidities that could be responsible of the poor symptoms' control and affect the patient's prognosis ([@B35]; [@B2]).

**Group C:** in group C, characterized by patients with low symptoms burden but high number of moderate/severe exacerbations, the initial therapy should be based on a single long acting bronchodilator, LABA or LAMA. The two studies that investigated this approach concluded that LAMA was superior to LABA in prevention of exacerbations and the GOLD authors recommend to start with a LAMA in this group of patients ([@B73]; [@B20]).

In those patients with persistent exacerbations, the addition of a second long acting bronchodilator or a combination of a LABA and an ICS may be beneficial ([@B47]). In SPARK study, the annual rates of moderate or severe exacerbations and all exacerbations were lower in the group of patients treated with GLY/IND combination versus GLY alone ([@B77]).

Due to an increase of the risk of development of pneumonia in some patients related to ICS, the first choice of combination therapy is LAMA/LABA even if not resulting from studies complaining patients in group C ([@B79]; [@B76]).

**Group D:** in group D, characterized by patients with high symptoms burden and high number of moderate/severe exacerbations, the initial therapy should be based on a combination bronchodilator therapy LAMA/LABA. This assumption is mainly based on results of [@B77], [@B76]) previously mentioned studies on combined LAMA/LABA versus monotherapies and LAMA/LABA versus ICS/LABA. Same results have been obtained in DYNAGITO trial with TIO/OLO dual therapy versus TIO alone ([@B11]). Patients belonging to group D could be naive patients (at first diagnosis), or could be shifted to this group coming from group B, in case of increased number of exacerbations during the previous year, or from group C, in case of increase of symptoms' burden. Those patients in treatment with combined LAMA/LABA bronchodilation, could be stepped up to triple-therapy LAMA/LABA/ICS in case of further exacerbations.

LAMA/LABA Single Inhaler: Devices
=================================

Bronchodilators consist in a complex and technological drug delivery system composed by a specific drug formulation and delivery device that made inhalable the drug inside. The devices are substantially divided in: active devices, where the energy needed to create the aerosol is generated by the same inhaler through a complex technological system, and passive devices where the aerosolization of the drug is dependent from the inhaled air stream.

Inhalation devices can be distinguished in three types: pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs) and, recently, soft mist inhaler (SMI, Boehringer Ingelheim). A comparison among inhaler devices in LABA/LAMA single inhaler treatment is reported in [Table 3](#T3){ref-type="table"}.

###### 

Principal differences between inhaler devices used to deliver LAMA/LABA FDC.

  Inhalers                         Drug delivered   Type        Characteristics
  -------------------------------- ---------------- ----------- -----------------------------------------------
  BREEZHALER^®^ (NEOHALER IN US)   GLY/IND          DPI         Must be loaded by patient
                                                                Single dose
                                                                Breath activated
  GENUAIR^®^                       ACL/FF           DPI         Pre-metered
                                                                Multidoses
                                                                Breath activated
                                                                Acustic feedback
  ELLIPTA^®^                       UMEC/VIL         DPI         Pre-meterd
                                                                Multidose
                                                                Breath activated
  RESPIMAT^®^                      TIO/OLO          SOFT MIST   Nebulizer
                                                                Dissipating a solution mechanically activated
  AEROSPHERE^®^                    GLY/FF           pMDI        Pressurized canister
                                                                Multidose
                                                                Manually activated
                                                                

LAMA, long acting muscarinic antagonist; LABAs, long acting beta agonists; GLY, glycopyrronium; IND, Indacaterol; DPI, dry powder inhaler; ACL, aclidinium; FF, formoterol fumarate; UMEC, umeclidinium; VIL, vilanterol; TIO, tiotropium; OLO, olodaterol; pMDI, pressurized metered dose inhaler.

Pressurized Metered Dose Inhalers
---------------------------------

In pMDIs the active drugs are dissolved or suspended in a propellant, a mixture of propellants, or a mixture of solvents and they are delivered via a compact pressurized aerosol dispenser (canister) by pushing the canister down into the holder. The canister contains several 100s metered doses of the medication. PMDIs are therefore not breath-activated and require the user to coordinate pressing down the canister and inhaling the medication.

Dry Powder Inhalers
-------------------

Dry powder inhalers contain the drug in dry state; the devices are usually constituted by a powder formulation, a dose metering mechanism that contains or measures a single dose of the drug, a powder de-agglomeration principle and a mouthpiece ([@B24]). The vast majority of DPIs are breath-actuated devices, using a passive mechanism, without the need of patient-device coordination; for a proper dose release the patient is required to make a minimal inspiratory effort.

The delivery of the formulation is consequent an active process usually initiated by an inhalation maneuvre of the patient; then the drug formulation is de-agglomerated or dispersed in an aerosol of small and inhalable particles of active agent and excipients. Each of these processes is dependent from several factors such as the powder formulation, the DPI used and patient' inspiratory effort. Indeed, in DPIs the inhalation maneuver is crucial and reflects the deposition rate of active principle in the respiratory tract; each DPI device has a different inhalation maneuver and the ability to perform a correct process is dependent from patient's characteristics such as age and clinical condition ([@B10]; [@B37]; [@B55]; [@B29]; [@B38]).

DPIs up to now used in the delivery of LAMA/LABA drugs for COPD patients are:

*Breezhaler*^®^ (Novartis, A.G., Basel, Switzerland) is a single-dose, breath-actuated DPI that releases a dry powder contained a pierced gelatin capsule loaded in the device by the patient before the inhalation. Brochodilators combination used is GLY/IND.

*Genuair*^®^ (AstraZeneca, Cambridge, United Kingdom) is a pre-metered multidose, breath-actuated, medium-resistance DPI; it provides both visual and acoustic feedback to indicate the correct inhalation of the dose. Bronchodilators combination used is ACLI/FF ([@B69]).

*Ellipta*^®^ (GlaxoSmithKline, Brentford, United Kingdom) is a pre-metered multidose, breath-actuated DPI; bronchodilators combinations used is UMEC/VIL ([@B33]).

Some studies investigated satisfaction, preference, and error occurrence of these DPIs. The preference of the patients and his skills in using the inhaler device can affect the effectiveness of the treatment. The ease of use is one of the most important characteristics the a device must have, in particular for elderly because they represent a huge part of patients affected by COPD ([@B44]). The recent study conducted by [@B44] compared these three devices and evaluated satisfaction, error occurrence during use of DPIs (evaluating critical and non-critical errors). Authors demonstrated that Breezhaler^®^ had the highest score for "comfort"; this may be related to the shape, size of the device in particular for female population, but Breezhaler^®^ had a significantly lower score for "ease of dose preparation." When authors investigated the "clarity to indicate correct dose preparation" and "clarity of indicate correct inhalation" Genuair^®^ received higher scores and this is due to the devices feedback mechanism that informs the patient to the correct preparation and inhalation of the loaded dose. Indeed, adherence to therapy is strictly related to the patient's confidence of regular inhalation of the drug ([@B58]). Satisfaction varies with the age of patients; younger patients gave higher scores to Ellipta^®^ than Breezhaler^®^ for "ease of operation" and "handling time," and this results suggest that handling procedures of Ellipta^®^could be difficult for the older population ([@B66]; [@B33]).

Comparing pMDIs and DPIs
------------------------

Pressurized metered dose inhaler and DPIs have their advantages and disadvantages. PMDIs require the user to coordinate pressing down the canister and inhaling the medication while DPIs are activated by breath; however, the inspiratory flow rate is a disadvantage of DPIs. The rate required to deliver the medication in pMDI inhalers is low (about 30 L/min) while the rate required for DPIs is higher (differs based on the build of the inhaler). This would make it more difficult for some patients to be able to deliver the medication properly. DPIs also require the patient not to disperse medication via exhalation into the device prior to using. Another disadvantage of pMDIs is the propellant; previously chlorofluorocarbon (CFC) was used now substituted by hydrofluoroalkane (HFA) and this can cause the inhaler to be more expensive.

Soft Mist Inhaler
-----------------

Soft mist inhaler Respimat^®^ is one of the more recently inhalers available; it's a nebuliser dissipating a solution composed by fine droplets of active agents. SMI is different from traditional nebuliser since it is portable and doesn't require a power source to work because it's activated mechanically. As pMDIs, the formation of the aerosol is instantaneous but for a correct inhalation it's required a higher coordination ([@B36]). Nevertheless, even if SMI takes a longer time to generate an entire aerosol, the nebulization is emitted in a slow-moving mist fashion, allowing a higher lung deposition ([@B18]). Due to the combination of smaller particle size, lower velocity and longer duration of the nebulization, a smaller dose of bronchodilators ensure the same level of efficacy and safety than metered dose inhalers. An higher lung deposition of nebulized drugs with SMI was demonstrated with a radio labeled drug particles ([@B52], [@B51]; [@B65]; [@B57]; [@B3]).

LAMA/LABA combination administered with Respimat^®^ is TIO/OLO [@B17] compared some devices in terms of patients' preference and acceptability; Respimat^®^ and Genuair^®^ were preferred to Breezhaler^®^ reporting less difficulties in understanding maneouvers for activate and correctly practicing the inhalation. Respimat^®^ has been judged the easiest to use, the less problematic and the most easy learned device at first attempt of use ([@B17]).

Critical Issues for LABA/LAMA Combinations in a Single Inhaler Therapy for COPD
===============================================================================

Dual bronchodilation treatment with LAMA/LABA FDC has demonstrated to be able to improve quality of life in COPD patients in terms of symptoms scores, rescue medication use ([@B70]) and lung hyperinflation when compared to placebo. In comparison to in several trials ([@B7]; [@B15]; [@B19]; [@B41]; [@B21]; [@B46]) as exercise tolerance ([@B9]). Moreover LAMA/LABA combinations have been noted to be superior compared to LABA/ICS combined treatment for COPD with at least one exacerbation in the previous year ([@B76]). A meta-analysis of heterogeneous studies comparing LAMA/LABA with LABA/ICS ([@B27]) concluded that LAMA/LABA has fewer exacerbations, a larger improvement of FEV~1~, a lower risk of pneumonia, and more frequent improvement in quality of life indicators.

Clearly none of the pharmacological treatments have ever shown a significant impact on COPD mortality, however we believe that the effects of the LABA/LAMA combination treatment observed improving patient quality of life represent main issues in the treatment of COPD.

Trials Limits
-------------

Concerns have been raised about the ability of large trials to actually identify the potential benefits of the investigated treatments. In particular, classical trials focused on the benefits of lung function (FEV~1~ changes in particular) as a primary endpoint and this could lead to an underestimation of the impact of the treatments studied on the improvement of endurance symptoms, frequency of exacerbations and hospitalizations and quality of life in general. It has also emerged how focusing on the change in FEV~1~ is deeply influenced by the choice of patients enrolled and may not translate into real life in an equally effective treatment, or vice versa fails to highlight an effective clinical impact in patients who, however, qualitatively improve quality of life performance. For these reasons clinical trials aimed at the ability to detect different endpoints capturing different aspects of COPD pathobiology such as real life clinical improvement are claimed. It is important to underline that the results of the different meta-analysis reported need to be taken with caution because of differences in the studied population and in the outcomes. This heterogeneity may result in difficulties to translate results in real life. Moreover LAMA/LABA direct comparison in head-to-head trials would be suggested.

### FDCs Are Better Than Monocomponent Treatment

The administration of two drugs simultaneously with the same device should ensure a better adherence to the treatment ([@B67]) Using together two bronchodilators with different mechanism of action can overcome specific patient dissimilarities in the response to different treatments ([@B14]), which may be due to different distribution of different receptors (beta agonists and muscarinic) in the lungs ([@B28]; [@B13]). However, the impossibility of change in the individual dosages of the two components may lead to potential problems in relation to individual side effects to one of the components. In the clinical trials these problems have never been observed and all LAMA/LABA FDC have shown optimal tolerability profiles. However, only the observation in real life clinical setting can reassure us about this aspect. Until now, the experiences reported in the daily clinical practice have given encouraging results, but we should keep the guard high in the detection of possible tolerance problems, especially in complex patients with multiple associated diseases usually excluded from clinical trials.

Dosing and Administration
-------------------------

It is necessary to underline that the various LAMA/LABA combinations available on the market are provided in a single fixed dose regimen, which allows poor treatment flexibility and the impossibility of administering different doses to different patients (e.g., in the presence of relevant differences in BMI in patients routinely excluded from large clinical trials).

Some other aspects may generate uncertainties in the interpretation of data received from trials and in the prescription or dispensation of the drug: some formulations require one puff/administration some others two consecutive puffs/administration. Some of the LAMA/LABA combinations are provided in regimen of two administrations per day (ACL/FF disposable in US and EU, GLY/IND 15,6/27,5 μg disposable only in US, GLY/FF disposable only in US), others in OD formulations (UMEC/VIL and TIO/OLO both disposable in US and EU and GLY/IND 50/110 μg disposable only in EU). In particular It should be noted that the GLY/IND associations in the US is available only at a lower dosage than that used in clinical trials ([@B75]; [@B79]; [@B76]) in relation to the differences in the US-approved IND dosage compared to the one approved in the EU.

All these differences in the regimens of administration must be kept in mind and could disorient the less experienced prescribers and the patients switching from one treatment to another.

A separate chapter deals with the treatment of the differences related to the different delivery systems of the different LABA/LAMA combinations. Most of the inhalers for the LABA/LAMA associations are DPI except SMI for Stiolto^®^ and pMDI for Bevespi^®^.

As before discussed each inhaler type has pros and cons that must be considered in the selection of a device for a particular patient. The DPIs, SMI and pMDIs present therefore differences in the size of the particles carrying the drug and therefore in the ability to reach the lung tissue more or less deep. The flow rate able to activate the different inhalers, the need for greater or less coordination of the patient and the preferences of the patients regarding the "taste" of the different formulations are all elements that will play a fundamental role not yet studied in the daily clinical application of these formulations.

Future Directions
=================

Future studies should indicate clinicians the results of head-to-head comparisons among the different LABA/LAMA associations in order to make less empirical the choice of the combination to be used. Since none of the available LAMA/LABA FDCs have been compared in head-to-head trials, they can only be weighed against each other by indirect comparisons as meta-analysis. Conclusions of that meta-analysis should be interpreted with great caution because of differences in population studied, and differences in primary and co-primary outcomes.

A recent comparison meta-analysis was not conclusive due to the heterogeneity of phase III studies and the few number of studies for some of the investigated drugs (ACL/FF and GLY/FF in particular), but confirmed that dual bronchodilation was always more effective than LABA or LAMA alone, both in lung function and quality of life indices ([@B12]). This meta-analysis suggested that among the different FDCs may exist a gradient of effectiveness, UMEC/VIL slightly improving the effects of GLY/IND (-12 mL), TIO/OLO (-30 mL), and ACL/FF (-49 mL), though statistically significant differences were not observed.

Recently [@B32] provided data about two cross-over trials comparing efficacy and safety of GLY/IND twice-daily 15.6/27.5 μg versus once-daily UMEC/VIL 62.5/25 μg. Both treatments provided clinically meaningful and comparable bronchodilation. Non-inferiority of GLY/IND to UMEC/VIL could not be declared although between-treatment differences were not clinically relevant ([@B32]).

[@B30] published data from a 12 weeks' treatment study with UMEC/VIL 62.5/25 μg that provided similar (non-inferior) improvements in lung function, symptoms, and health status, as well as comparable safety profiles to those achieved with free combinations of a LABA plus LAMA (TIO 18 μg + IND 150 μg).

In order to provide safety and efficacy data to treating physicians, further head-to-head comparative studies applying appropriate non-inferiority limits should be conducted.

Triple Therapy
--------------

It is necessary spending few words on the role of adding ICS to the LABA/LAMA combinations in some particular COPD patient categories. The so-called "Triple therapy" has demonstrated to produce benefits in COPD patients in GOLD group D ([@B62]) FF 6 μg, GLY bromide 12.5 μg, and beclomethasone 100 μg was compared to FF and beclomethasone in reducing exacerbation frequency providing a -12% of exacerbation frequency. Moreover, TRINITY study compared FF 6 μg, GLY 12.5 μg, and beclomethasone 100 μg to TIO and found that the triple combination therapy resulted in a 20% reduction in the rate of moderate-to-severe COPD exacerbations, improvement in pre-dose FEV~1~ in COPD patients with frequent exacerbations ([@B72]). However, the results of head to head comparison between LAMA/LABA and LAMA/LABA/ICS combinations are still pending. Recently the TRIBUTE study ([@B53]) compared single-inhaler triple combination of beclometasone, FF, and GLY (87 μg/5 μg/9 μg) 2 inhalations twice per day versus a single-inhaler dual bronchodilator combination of GLY/IND (43 μg/85 μg) one inhalation daily in a group of symptomatic COPD with severe or very severe airflow limitation and at least one moderate or severe exacerbation in the previous year. Authors reported that triple therapy significantly reduced the rate of moderate-to-severe exacerbations compared with GLY/IND, without increasing the risk of pneumonia. Confirming the possible importance of triple treatment in more severe COPD patients. Currently another study is comparing TIO/OLO with ICS/LABA/LAMA triple therapy but results are still waited ([@B16]).

[@B39] recently we compared 52 weeks of a OD combination of FF/UMEC/VIL 100/62.5/25 μg with FF/VIL 100/25 μg and UMEC/VIL 62.5/25 μg. Authors observed that Triple therapy with FF/UMEC/VIL resulted in a lower rate of moderate or severe COPD exacerbations than the other dual combinations in this population. Triple therapy also resulted in a lower rate of hospitalization due to COPD than UMEC/VIL association ([@B39]).

Treatment (IMPACT) study will evaluate the efficacy and safety of FF/UMEC/VIL 100/62.5/25 μg versus FF/VIL 100/25 μg or UMEC/VIL 62.5/25 μg, over a 52-week treatment period on COPD D patients. The study was designed to assess not only the value of triple therapy compared to dual therapy, but also the relative comparative advantages of the two dual therapies (ICS/LABA and LABA/LAMA) ([@B54]).

Going ahead, a more personalized approach to therapy is required since we have understood that with the term COPD we define a disease characterized by persistent airways obstruction but at the basis of this has been demonstrated the presence of different phenotypes ([@B50]).

In fact, if we consider asthma COPD overlap syndrome (ACOS), it is clear that identification of these patients will make it possible to get more benefit from the use of ICS compared to patients with other phenotypes. Moreover, the identification of COPD patients with elevated eosinophil count in the sputum may guide the physician in the choice of treatment adding ICS to bronchodilators. These examples allow us to understand the importance of the knowledge of the physio-pathological bases of COPD that will allow in the future identifying treatments more and more tailored beyond the standardized classifications of COPD based on spirometry and frequency of exacerbations.

Conclusion
==========

LAMA/LABA combinations are recommended in COPD with persistent symptoms or with further exacerbations treated with monotherapy. LAMA/LABA combinations have a synergistic effect rather than just being additive one and have been shown to improve lung function, lung hyperinflation, exercise tolerance, exacerbations frequency and quality of life in COPD. However, a number of questions is still pending and under debate. It is now more and important identifying different phenotypes, so future data are warrant to make clear which combination is more favorable to use, in which patient and at which stadium of the disease, tailoring the treatment to be more and more personalized.
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